H.C. Wainwright slashes price target on Decibel Therapeutics Inc. [DBTX] – find out why.

Related

Decibel Therapeutics Inc. [NASDAQ: DBTX] traded at a high on 06/29/22, posting a 44.15 gain after which it closed the day’ session at $3.82. The company report on June 28, 2022 that Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


– 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear –.

– Data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer –.

The results of the trading session contributed to over 8908288 shares changing hands. Over the past one week, the price volatility of Decibel Therapeutics Inc. stands at 21.45% while the volatility over the past one month is 13.33%.

The market cap for DBTX stock reached $91.15 million, with 24.95 million shares outstanding and 11.23 million shares in the current float. Compared to the average trading volume of 79.00K shares, DBTX reached a trading volume of 8908288 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Decibel Therapeutics Inc. [DBTX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DBTX shares is $16.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DBTX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Decibel Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 15, 2021. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on October 22, 2021, representing the official price target for Decibel Therapeutics Inc. stock. Previously, the target price had yet another raise to $26, while SVB Leerink analysts kept a Outperform rating on DBTX stock.

The Average True Range (ATR) for Decibel Therapeutics Inc. is set at 0.36 The Price to Book ratio for the last quarter was 0.74, with the Price to Cash per share for the same quarter was set at 5.64.

How has DBTX stock performed recently?

Decibel Therapeutics Inc. [DBTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 61.86. With this latest performance, DBTX shares gained by 63.25% in over the last four-week period, additionally sinking by -21.72% over the last 6 months – not to mention a drop of -57.37% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DBTX stock in for the last two-week period is set at 75.04, with the RSI for the last a single of trading hit 80.69, and the three-weeks RSI is set at 70.11 for Decibel Therapeutics Inc. [DBTX]. The present Moving Average for the last 50 days of trading for this stock 2.32, while it was recorded at 2.72 for the last single week of trading, and 4.63 for the last 200 days.

Decibel Therapeutics Inc. [DBTX]: Deeper insight into the fundamentals

Return on Equity for this stock declined to -119.26, with Return on Assets sitting at -41.17.

Decibel Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.40.

Insider trade positions for Decibel Therapeutics Inc. [DBTX]

There are presently around $43 million, or 64.50% of DBTX stock, in the hands of institutional investors. The top three institutional holders of DBTX stocks are: ORBIMED ADVISORS LLC with ownership of 4,945,192, which is approximately 0% of the company’s market cap and around 20.20% of the total institutional ownership; TRV GP III, LLC, holding 3,139,685 shares of the stock with an approximate value of $8.32 million in DBTX stocks shares; and BLACKROCK INC., currently with $5.03 million in DBTX stock with ownership of nearly 73.071% of the company’s market capitalization.

Positions in Decibel Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 13 institutional holders increased their position in Decibel Therapeutics Inc. [NASDAQ:DBTX] by around 1,116,395 shares. Additionally, 16 investors decreased positions by around 1,037,024 shares, while 16 investors held positions by with 13,901,189 shares. The mentioned changes placed institutional holdings at 16,054,608 shares, according to the latest SEC report filing. DBTX stock had 4 new institutional investments in for a total of 283,237 shares, while 7 institutional investors sold positions of 109,337 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]